Novo Nordisk’s ADA Data: One Success, One Setback, and a Stock Under Pressure

Novo Nordisk shares drop 16% YTD after CagriSema fails non-inferiority vs Lilly's Zepbound; Zenagamtide Phase 2 shows strong weight loss; analysts hold rating.

Novo Nordisk closed a turbulent week on a sour note, with shares shedding 4.35% to EUR 37.35, leaving the stock down more than 16% since the start of 2025. The Danish pharma giant had come to the American Diabetes Association’s 86th Scientific Sessions in New Orleans armed with a thick deck of clinical updates — but the market homed in on two very different narratives.

The bright spot came from Zenagamtide, a combined GLP-1/amylin agonist. In a Phase 2 study involving 262 type 2 diabetes patients, the highest 40 mg dose delivered a 14.6% weight reduction and a 1.71 percentage point drop in A1C after 36 weeks. Crucially, investigators noted no plateau in weight loss at the higher doses, prompting Novo Nordisk to plan a Phase 3 start for the second half of 2026.

The other headline was far less favourable. The REDEFINE-4 head-to-head trial of CagriSema — a fixed-dose combination of semaglutide and a long-acting amylin analogue — showed patients lost 23% of their body weight over 84 weeks. But Eli Lilly’s Tirzepatide (Zepbound) achieved 25.5% in the same comparison, meaning CagriSema missed its primary non-inferiority endpoint. Novo Nordisk still expects an FDA decision on CagriSema by end of 2026 and intends to launch a higher-dose study, but the setback has sharpened investor scrutiny.

Competitive pressures are mounting from other corners too. Roche and Zealand Pharma unveiled Phase 2 data for Petrelintide, a selective amylin agonist that produced a 9% weight reduction with good tolerability. Meanwhile, a Stanford Medicine study flagged that roughly 10% of the population carry genetic variants in the PAM gene that could confer resistance to GLP-1 therapies, potentially capping the addressable market for Ozempic and Wegovy.

Beyond the clinic, Novo Nordisk is investing heavily to fortify its manufacturing and digital capabilities. On June 12 the company will officially inaugurate a renovated production facility in the Czech Republic, a site acquired from Novavax in 2024. It has also committed EUR 500 million to the Scaleup Europe Fund, which targets digital health and biopharma technologies. Through AI-driven solutions, the group aims to cut the time-to-market for new medicines by 10% to 15%, yielding estimated annual savings of EUR 50 million to EUR 70 million.

The Danish group remains an active buyer of its own stock. A current buyback programme of up to DKK 15 billion over twelve months includes an active tranche of up to DKK 11.2 billion in B?shares, running until February 1, 2027. By the end of May, Novo Nordisk had repurchased 17,889,179 B?shares at an average price of DKK 263.47, for a total outlay of DKK 4.71 billion. The programme underscores management’s confidence in free cash flow even as the pipeline must deliver.

The Street, however, remains cautious. Of 23 analysts polled, the consensus is a hold rating with a 12-month price target of USD 65.56. Only four firms recommend buying, while 18 sit on the fence and one says sell. Goldman Sachs reiterated a neutral stance on the stock earlier this month.

Technically, the shares are under pressure. The price sits below its 200-day moving average of EUR 41.67 and its 100-day average, with only the 50-day line at EUR 35.80 offering a thin floor. That level could quickly evaporate if selling resumes, putting the 52-week low from March at EUR 30.25 back in play.

The next major catalyst is Novo Nordisk’s R&D investor event on June 7, where executives will contextualise the ADA data. With 40 abstracts on display through June 8 — covering semaglutide in cardiovascular, renal, pulmonary, and metabolic indications — the company is betting that strong diabetes outcomes for CagriSema could help re?focus attention on its broader profile. For now, though, the market has made its judgment: one pipeline star is not enough to offset a very public miss.